BRCA mutations

January 12, 2021January 12, 2021

Lynparza Approved in Japan to Treat Certain Advanced Ovarian Cancers

News

Lynparza (olaparib) has been approved in Japan as a maintenance treatment for women with advanced ovarian cancer who responded to a first-line chemotherapy regimen containing bevacizumab, AstraZeneca and Merck announced in a ... Read more

January 5, 2021January 5, 2021

Trial Confirms Rubraca’s Clinical Benefit Over Chemotherapy

News

Rubraca (rucaparib) is superior to chemotherapy at prolonging life without disease worsening in people with advanced ovarian cancer who received at least two prior lines of chemotherapy, according to top-line data ... Read more

November 10, 2020January 12, 2021

Lynparza Combo Approved in EU as First-line Maintenance for Advanced Ovarian Cancer

News

The European Commission has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who ... Read more

August 18, 2020August 18, 2020

Large-scale Testing of BRCA Mutations Can Be Cost-Effective, Study Finds

News

Screening the overall population for mutations in the genes BRCA1 and BRCA2 that can cause breast and ovarian cancer is cost-effective in wealthier countries, from the viewpoint of both payers and society, an ... Read more

July 28, 2020July 28, 2020

Pamiparib Granted Priority Review in China for Treatment of Advanced Ovarian Cancer

News

China’s regulatory agency has granted priority review status to BeiGene‘s new drug application (NDA) requesting the approval of pamiparib, its investigational PARP inhibitor, for the treatment of advanced ovarian cancers. Priority review is ... Read more

July 21, 2020July 21, 2020

Small Inhibitor May Boost Effectiveness of PARP Inhibitors in Some Ovarian Cancers, Mouse Study Finds

News

A small inhibitor that prevents cells from making ribosomes — the machinery used to produce proteins — may improve the effectiveness of PARP inhibitors in ovarian cancers with mutations in DNA repair ... Read more

April 30, 2020May 12, 2020

FDA Approves Zejula as First-line Maintenance Therapy for Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Zejula (niraparib) as a first-line maintenance therapy for women with advanced ovarian cancer who responded to platinum-based chemotherapy, regardless of their BRCA mutation status. This indication ... Read more

August 2, 2019August 26, 2019

Gray Foundation Awards $3.75M to Study of BRCA Mutations in Ovarian and Other Cancers

News

The Gray Foundation awarded a $3.75 million grant to a researcher team to study how BRCA1 or BRCA2 mutations, along with other genetic anomalies, increase the risk of breast, ovarian, ... Read more

May 14, 2018

Researchers Discover Mutations Behind Resistance to PARP Inhibitors Like Lynparza

News

Scientists have found mutations in the poly ADP-ribose polymerase (PARP) gene that cause resistance to PARP inhibitor therapies — such as Lynparza (olaparib) — in a mouse model and in one ... Read more

March 21, 2018

Genetic Testing Helps Identify Ovarian Cancer Patients with BRCA Mutations, UK Study Finds

News

Genetic testing as part of routine cancer care, an approach called mainstreamed genetic testing, or MGT, is a feasible way to test BRCA mutations in ovarian cancer patients, a new U.K. study ... Read more